StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $16.64 | $15.28 | -8.17% | 0.3M |
| 05-12 | $15.05 | $13.27 | -11.83% | 0.5M |
| 05-13 | $13.69 | $15.24 | +11.32% | 0.3M |
| 05-14 | $15.17 | $14.61 | -3.69% | 0.1M |
| 05-15 | $14.61 | $13.05 | -10.68% | 0.2M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2018 2018-09-30 | Q2 2018 2018-06-30 | Annual 2017 2017-09-30 | Q2 2017 2017-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $50.00K | $50.00K |
Operating Income | $-5.08M | $-853.29K | $-5.22M | $-3.86M |
Net Income | $-1.17M | $-827.10K | $-5.03M | $-3.81M |
EPS (Diluted) | Not available | Not available | Not available | Not available |
Total Assets | $11.78M | $12.80M | $7.72M | $9.02M |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $3.73M | $5.82M | $4.57M | $3.65M |
Free Cash Flow OCF − CapEx | $-5.00M | $-694.84K | $-5.00M | $-3.78M |
Shares Outstanding | 5.33M | 5.33M | 1.50M | 10.52M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.